Productising business objectives. Strategist. Public Speaker. Digital Health Expert. Doctor. Runner. Earth Child

I create. Incorporating user-voice into products is my strength. I create elegant and intuitive products by capturing this voice. My diversity of skills delivers them in a structured, prioritised and outcome focused manner.

I solve. Problem solving aligned with the strategic vision and delivered with a detail-oriented-ness is a passion of mine. I connect the dots amidst chaos to make these solutions feasible and scalable.

I inspire. People are the most valuable asset of an organisation. Intelligent, imaginative and motivated people together in teams build the future. My leadership and empathy create and lead such teams. I create teams that inspire the world

I learn. In both personal and professional life upping my ante is a constant need. I learn, I validate, I learn again. I am a product manager, venture capitalist, growth strategist, health-tech ecosystem expert

* Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Neuroscience is advancing at an unprecedented rate and Ipsen is at the forefront of this transformation. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €2.576 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 37 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. * Ipsen est un groupe biopharmaceutique mondial de spécialité focalisé sur l’innovation et la médecine de spécialité. Il développe et commercialise des médicaments innovants dans trois domaines thérapeutiques ciblés – l’oncologie, les neurosciences et les maladies rares. L’engagement d’Ipsen en oncologie est illustré par son portefeuille croissant de thérapies visant à améliorer la vie des patients souffrant de cancers de la prostate, de tumeurs neuroendocrines, de cancers du rein et du pancréas. Avec un chiffre d’affaires de près de 2 576 milliards d’euros en 2019, Ipsen commercialise plus de 20 médicaments dans plus de 115 pays, avec une présence commerciale directe dans plus de 37 pays. La R&D d'Ipsen est focalisée sur ses plateformes technologiques différenciées et innovantes situées au cœur des clusters mondiaux de la recherche biotechnologique et en sciences de la vie (Paris-Saclay, France ; Oxford, Royaume-Uni; Cambridge, Etats-Unis). Il rassemble environ 5 700 collaborateurs